The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials by unknown
Sun et al. Systematic Reviews 2013, 2:103
http://www.systematicreviewsjournal.com/content/2/1/103PROTOCOL Open AccessThe efficacy of dapagliflozin combined with
hypoglycemic drugs in treating type 2 diabetes:
protocol for meta-analysis of randomized
controlled trials
Yu-nan Sun1, Yi Zhou1, Xi Chen1, Wen-si Che1 and Siu-wai Leung1,2*Abstract
Background: Dapagliflozin is a first-in-class oral sodium glucose co-transporter 2 (SGLT2) inhibitor. It is often used
in combination with conventional anti-diabetic drugs such as metformin, glimepiride, and insulin in treating type 2
diabetes (T2D). It not only reduces glucose reabsorption in the kidney but also increases renal glucose excretion.
Some studies found the actions of dapagliflozin independent of insulin and free from risk of weight gain. This
meta-analysis aims to evaluate whether dapagliflozin is synergistic with other anti-diabetic drugs without risk of
weight gain.
Methods/Design: This meta-analysis will include the randomized controlled trials (RCT) evaluating the efficacy of
dapagliflozin as an add-on drug in treating T2D for >8 weeks with the outcome measures glycosylated hemoglobin
(HbA1c), fasting plasma glucose (FPG) and body weight. Information of relevant RCTs will be retrieved from major
databases including PubMed, Cochrane Library, Embase, ClinicalTrials.gov, and Google Scholar according to a
pre-specified search strategy. Google and manual search will find other unpublished reports and supplementary
data. Eligible RCTs will be selected according to pre-specified inclusion and exclusion criteria. Data will be extracted
and input into a pre-formatted spreadsheet. The Cochrane risk of bias tool will be used to assess the quality of the
eligible RCTs. Meta-analysis based on the random-effects model will be conducted to compare the changes of
HbA1c (%), FPG (mmol/L), and body weight (kg) between dapagliflozin arm and placebo arm. Publication bias will
be evaluated with a funnel plot and the Egger’s test. Heterogeneity will be assessed with the I2 statistics. Sensitivity
analysis will be conducted on follow-up periods. The evidential quality of the findings will be assessed with the
GRADE profiler.
Discussion: The findings of this meta-analysis will be important to clinicians, patients, and health policy-makers
regarding the use of dapagliflozin in T2D treatment.
Study registration: PROSPERO registration number: CRD42013005034
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The efficacy of common anti-diabetic drugs (including
metformin, sulfonylureas, nonsulfonylurea secretagogues,
alpha glycosidase inhibitors, thiazolidinediones, glucagon-
like peptide-1 analog, and dipeptidyl peptidase-4 inhibi-
tors) is insulin-dependent [1]. Their efficacy diminishes
with the declines of the function of pancreatic islet β-cells
during the progression of type 2 diabetes (T2D) [2]. Sul-
phonylureas and thiazolidinediones cause weight gain,
which will further worsen insulin resistance [3]. It came as
no surprise that approximately two-thirds of diabetics
in Europe [4] and the United States [5] under con-
ventional treatment could not meet the goal of glu-
cose control. By contrast, as a highly selective inhibitor of
sodium glucose co-transporter 2 (SGLT2), dapagliflozin is
distinctive in its insulin-independent action on reducing
reabsorption of glucose particularly by the proximal tu-
bule in the kidney to eliminate more glucose from plasma
into urine [6-8]. Dapagliflozin would enhance glucose
control without adverse effects on body weight, blood
pressures, and lipids like conventional anti-diabetic drugs
[9,10]. These claimed advantages of dapagliflozin would
be beneficial for combining conventional anti-diabetic
drugs with dapagliflozin in treating T2D. However, these
claims were made by individual clinical studies, not well-
established by the available systematic reviews and meta-
analysis. Three existing meta-analysis reports did not
focus on dapagliflozin but addressed the efficacy issues
of SGLT2 inhibitors in general [3,11,12]. The only
meta-analysis [13] on dapagliflozin in particular still
lacked analysis of publication bias and sensitivity to
various possible factors as the PRISMA guideline for
meta-analysis reporting. Although a subgroup analysis
on dapagliflozin monotherapy was available in the
meta-analysis [13], it did not provide a specific ana-
lysis of the efficacy of dapagliflozin combined with
other anti-diabetic drugs. All these four meta-analysis
studies were not registered before their conduct. The
present meta-analysis aims to evaluate the efficacy of
dapagliflozin in combination with conventional anti-
diabetic drugs for glucose control as measured by the
changes of glycosylated hemoglobin (HbA1c) and fast-
ing plasma glucose (FPG). The body weight data will
be analyzed to test whether the claim that dapagliflozin
does not affect body weight (that is, no weight gain) was
sound across relevant studies.
Methods/Design
This protocol specifies the conduct and reporting of a
systematic review and meta-analysis in compliance with
the guideline Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA). The protocol has
been registered in the PROSPERO database and assigned
an identifier CRD42013005034.Date sources
Bibliographical databases for literature search include
PubMed, Cochrane Library, Embase, Google Scholar, and
ClinicalTrials (http://www.clinicaltrials.gov). Our search
strategy will include main keywords ‘dapagliflozin’ and
‘diabetes’ (Appendix). Google search will be conducted to
find other RCT information that is not available from bib-
liographical databases. Manual search will be conducted
to track relevant RCTs that are not obviously indexed
by normal keywords. Study selection will be docu-
mented and summarized in a PRISMA-compliant flow-
chart (Additional file 1: Figure S1).
Eligibility criteria
The retrieved studies will be selected according to the
checklist in Additional file 2 and the eligibility criteria
listed below:
Study design
Only RCTs will be included. Observational, cohort,
case–control, case series, and laboratory studies will be
excluded.
Follow up periods
As long enough follow-up time is required for observing
changes in HbA1c levels, this meta-analysis will include
only the RCTs with follow-up periods >8 weeks.
Participants
This meta-analysis will include only the RCTs on adult
T2D patients (aged ≥18 years).
Interventions
This meta-analysis will include only the RCTs on the ef-
ficacy of dapagliflozin combined with conventional anti-
diabetic drugs. The RCTs on dapagliflozin monotherapy
will be excluded.
Comparators
This meta-analysis will include the RCTs employing
placebo combined with conventional anti-diabetic drugs
as the controls. The RCTs employing only placebo as
the control group will be excluded.
Outcomes
This meta-analysis will include the RCTs measuring
HbA1c, FPG, and body weight as the outcomes. The RCTs
without all these three outcomes will be excluded.
Study selection
At least two reviewers will use the same eligibility evalu-
ation form to evaluate the studies according to the eligi-
bility criteria. Disagreement of their evaluation will be
resolved by discussion.
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Data from each included RCT will be extracted by one
reviewer and verified by another. In addition to the out-
come measures, the following characteristics of the veri-
fied RCTs will be extracted: (1) authors (and publication
year), (2) interventions (doses of dapagliflozin and the
drug used in combination), (3) characteristics of partici-
pants, (4) follow-up periods, and (5) conclusion. The
extracted data will be tabulated (Additional file 3:
Table S1) for further analysis.
Quality assessment
We will assess the design, execution, and reporting of
the included RCTs according to the Cochrane risk of
bias tool (Additional file 4: Table S2) [14]. The quality
of each RCT will be assessed by one reviewer and verified
by another. The quality of evidence will be determined
with the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system [15]. The
analysis will be conducted with GRADE profiler 3.2.
Data synthesis and analysis
All statistical analysis will be performed with R 3.0.1 soft-
ware (http://www.r-project.org/). Meta-analysis based on
the random-effects model will be conducted with ‘meta-
phor’ package [16]. Continuous data such as the changes
of HbA1c (%), FPG (mmol/L), and body weight (kg) will
be presented as adjusted mean differences with 95% confi-
dence intervals. A subgroup analysis will be conducted ac-
cording to different drug combinations. The effects of
follow-up periods and drug dosages will be assessed by
meta-regression.
Publication bias will be evaluated with a funnel plot
(that is, a plot of the effect sizes against their standard
errors) and Egger’s regression test. Heterogeneity will be
assessed with the I2 statistic, which is the proportion of
total variance observed between the RCTs attributable
to differences between RCTs rather than to sampling
errors.
Sensitivity analysis
Sensitivity analysis will be performed to evaluate the ro-
bustness of the meta-analysis results. We will exclude
the RCTs with some extreme features, for example, long
follow-up periods (>24 weeks) or high risks of bias (if any),
for sensitivity analyses. We would claim the meta-analysis
to be robust or reliable if the sensitivity analysis does not
significantly change the final results.
Discussion
This meta-analysis will synthesize evidence from avail-
able RCTs on the efficacy of dapagliflozin in combined
use with any conventional anti-diabetic drug, particularly
the efficacy measured by the outcomes in HbA1c, FPG,and the body weight. The evidence would be useful to
clinicians, patients, and health policy-makers regarding

















Additional file 1: Figure S1. Flow diagram.
Additional file 2: Eligibility criteria for screening studies.
Additional file 3: Table S1. Basic characteristics of randomized
controlled trials included in the systematic review.
Additional file 4: Table S2. The Cochrane Collaboration’s tool for
assessing risk of bias.
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